Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Slowing the Spread of Advanced Pancreatic Cancer
Researchers are testing a kinase inhibitor that is used to treat lung diseases, including a type of lung cancer, against pancreatic cancer.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
A New Drug to Target Cancer Cell Enzymes
This trial remains active but is no longer recruiting participants. In patients with metastatic pancreatic cancer, researchers are comparing FOLFIRINOX,…
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Living Longer with Pancreatic Neuroendocrine Tumors
Dr. Pamela Hodul explains some of the different types of pancreatic neuroendocrine tumor (PNET) and how rare they are, and some treatment options.
Testing a New Drug on Advanced Pancreatic Neuroendocrine Tumors
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).